Accordingly, CAF treatment with another somatostatin analogue octreotide, which does not activate sst1 (Schmid, 2008), was not able to reverse the chemoprotective effect conferred by the corresponding CAF-CM, nor directly regulate apoptosis, on gemcitabine-treated pancreatic cancer cells (Panc-1 or BxPC-3 cells), as measured by various apoptosis and survival assays (executioner caspase activity, Supplementary Fig S6A–B; MTT, Supplementary Fig S6C–D; caspase-3 and PARP cleavage, Supplementary Fig S6E). This evidence concerns the gene SST and familial pancreatic carcinoma.